From discovery to commercialization, in one place
Fragmentation is the tax the bioeconomy pays every day. A single, connected surface — from paper to product — is worth more than any individual feature on it.
Every biotech founder ships the same nine documents in the first eighteen months of a company: an invention disclosure, an IP landscape, a BioPlan, a market model, a regulatory strategy, a manufacturing plan, a clinical outline, a pitch deck, and a data room. Today those live in nine tools, five folders, and three consultants — and every handoff loses fidelity.
The single largest unlock in the modern bioeconomy is not another AI feature. It is putting all nine artifacts on one connected surface, where an edit to the IP claim propagates into the pitch deck, the regulatory plan, and the LP update — automatically, and with a clean audit trail.
That is what BioGrowth is. Not a suite of tools. One continuous surface for turning a discovery into a company.